ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2015
[Advances on driver oncogenes of non-small cell lung cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03330834 (Safety and Toxicity of CAR-T Cell Immunotherapy in Patients With Advanced Lung Cancer After Standard Treatment Failure), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Toxicity of CAR-T Cell Immunotherapy in Patients With Advanced Lung Cancer After Standard Treatment Failure: A Single-Arm and Single-Center Phase I Clinical Study
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.Pharmaceutics · 2023Review
- Review
- Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer.Chronic diseases and translational medicine · 2017Article
- Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report.International journal of clinical and experimental pathology · 2015Article
- Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenocarcinoma and squamous cell carcinoma are the most common histological types of non-small cell lung cancer (NSCLC). Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. With next-generation sequencing (NGS) which having multiple and high-throughput genotyping is wildly used and promoted, make the detection of patients gene composition from a tiny tumor biopsy specimens become possible, initiate the clinical studies based on the genetic characteristics, and promote the progress of molecular typing in NSCLC. So far, about 60% of lung adenocarcinoma has been found harbouring driver oncogenes, the rate of lung squamous cell carcinoma driven genes detection has gradually improved, in which epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor 1 (FGFR1), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) and so on plays important roles. The currently effective targeted therapies is mainly used against EGFR, ALK, etc. In this review, we will report the mainly advances on some latest driver mutations of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.